2020
Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens
Verma N, Puri A, Essuman E, Skelton R, Anantharaman V, Zheng H, White S, Gunalan K, Takeda K, Bajpai S, Lepore TJ, Krause PJ, Aravind L, Kumar S. Antigen Discovery, Bioinformatics and Biological Characterization of Novel Immunodominant Babesia microti Antigens. Scientific Reports 2020, 10: 9598. PMID: 32533024, PMCID: PMC7293334, DOI: 10.1038/s41598-020-66273-6.Peer-Reviewed Original ResearchConceptsPotential biological functionsBiological functionsCellular localization studiesB. microtiEvolutionary relationshipsDomain architectureBioinformatics analysisRecombinant proteinsExtracellular domainLocalization studiesPrimary causative agentUnrelated groupsE. coliBiological characterizationNovel assayIntraerythrocytic parasitesBabesia microtiDistinct classesProteinCausative agentAntigen discoveryGlobal public health impactB. microti antibodiesB. microti antigenTransfusion of blood
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis